Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mach7 Technologies ( (AU:M7T) ) has issued an announcement.
Mach7 Technologies announced it will release its FY25 results on 27 August 2025, followed by a webinar hosted by CEO Teri Thomas and CFO Dyan O’Herne for the investment community. This announcement underscores Mach7’s commitment to transparency and engagement with investors, potentially impacting its market positioning and stakeholder relations positively.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.95 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies (ASX:M7T) is a leading provider of medical imaging software, offering advanced data management and diagnostic viewing solutions to healthcare organizations globally. Their flagship product, the Mach7 Enterprise Imaging Solution, integrates a Vendor Neutral Archive, the eUnity Enterprise Diagnostic Viewer, and diagnostic workflow applications, providing flexibility and scalability for diverse healthcare networks.
Average Trading Volume: 273,571
Technical Sentiment Signal: Sell
Current Market Cap: A$86.94M
See more data about M7T stock on TipRanks’ Stock Analysis page.